Anti-angiogenic therapies in prostate cancer

Area of Science:

• Oncology
• Cancer Research
• Medical Science

Background:

• Prostate cancer (PCa) is a leading cancer in men, with limited options in the castrate-resistant metastatic stage.
• Angiogenesis, the formation of new blood vessels, is crucial for PCa progression.
• Anti-angiogenic therapies have been investigated in clinical trials (CTs) for PCa, based on preclinical data.

Discussion:

• Despite preclinical promise and observed anti-tumor activity in CTs, no anti-angiogenic agents are currently approved for PCa.
• This editorial reviews the current clinical evidence for anti-angiogenic therapies in PCa treatment.
• The focus is on the latest findings from ongoing and completed clinical trials.

Key Insights:

• Preclinical models suggest anti-angiogenesis is a viable strategy for PCa.
• Clinical trials have shown some anti-tumor effects but have not yet led to drug approval.
• Further research is needed to overcome challenges and identify effective anti-angiogenic treatments for PCa.

Outlook:

• Continued investigation into anti-angiogenic therapies is essential for advancing PCa treatment.
• Future research may focus on combination therapies or novel drug targets.
• Optimizing patient selection and treatment regimens will be key to successful clinical application.